Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$45.60 USD
-0.55 (-1.19%)
Updated Sep 18, 2025 04:00 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BMY 45.60 -0.55(-1.19%)
Will BMY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMY
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top Stock Reports for Exxon Mobil, AMD & Caterpillar
Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?
Other News for BMY
Peel Hunt Keeps Their Buy Rating on Bloomsbury Publishing (BMY)
Dividend Harvesting Portfolio Week 237: $23,700 Allocated, $2,573.68 In Projected Dividends
Is BMY compressing before expansion? Bollinger Band Squeeze shows up after sliding 0.41%
Bloomsbury Publishing Appoints New CFO to Drive AI and Digital Growth
J&J studies find icotrokinra more effective than deucravacitinib for psoriasis